Abstract: A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types.A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate.A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substantially monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent.

Abstract: A CEA immunoassay includes a step for inactivation of interfering human antibodies against non-human immunoglobulin, wherein a buffered serum or plasma sample at about pH 5.0 is heated at about 90.degree. C. for about 15 minutes prior to sandwich assay using capture and probe monoclonals that bind to heat-stable CEA epitopes.

Abstract: Antibodies and antibody conjugates which have been modified by conjugation to, or exposure thereon, of glycoside residues that bind to the human hepatic asialoglycoprotein receptor clear rapidly from the circulation. Use of such modified antibodies and antibody conjugates for imaging and therapy of tumors and infectious lesions is advantageous when the antibodies are administered by a regional route, or when intravenous administration is accompanied by injection of a competitive hepatic lectin binding inhibitor to control the rate of clearance and optimize uptake by the target tissues.

Abstract: An antibody or antibody fragment is modified by chemical linkage to a synthetic poly(amide/urea/thiourea) which contains a plurality of boron atoms or other functional groups, conferring upon the resultant conjugate desirable properties as a diagnostic and/or therapeutic agent. In a preferred embodiment, boron-containing groups are conjugated to the antibody/fragment such that the resultant conjugate contains 50-2000 boron atoms, with about 96% Boron-10 isotope content, to produce conjugates useful for neutron-activated radiotherapy of tumors or pathological lesions.

Abstract: A non-enzymatic method of immunohistochemical staining uses a bound electron transfer agent to achieve amplification of antibody binding to specific antigens of interest in a histology or cytology specimen. A preferred embodiment uses a bound phenazine, which is reduced with a soluble reducing agent, and which in turn reduces a tetrazolium salt, to precipitate a formazan dye at the site of primary antibody binding to the antigen of interest. Reagents and kits for use in the method are also provided.

Abstract: Immunoassay system for determining the amount of a polyvalent ligand in a liquid test sample, and based on:(a) an insoluble phase to which is bound a separation specific binding substance which does not bind said ligand;(b) a capture specific binding substance which specifically binds said ligand, and which is itself specifically bound by said spearation specific binding substance; and(c) a probe specific binding substance which specifically binds said ligand at a site which is accessible when said ligand is bound to said capture specific binding substance, said probe specific binding substance being not substantially bound by said separation specific binding substance, and being detectable by at lease one detection procedure.

Abstract: A method for determining the presence of an antigen in a liquid sample. The method includes incubating the sample with an antibody which specifically binds an epitope on the antigen in the presence of a given quantity of an anti-idiotype antibody which specifically binds an epitope on the hypervariable region of the antibody. Also, a method of producing a monoclonal anti-idiotype antibody by fusing lymphocytes from an animal in which a tumor capable of secreting idiotype antibodies has been grown, with myeloma cells.

Abstract: A conjugate of methotrexate to an antibody is prepared by loading methotrexate onto an aminodextran, then specifically conjugating the polymer carrier to the carbohydrate portion of an antitumor antibody, using a reduced Schiff base linkage. The conjugate is useful for tumor targeted therapy.

Abstract: A selective bifunctional sequential linker has the formulaY.dbd.C.dbd.N--Q--A--C(O)--Zwherein Q is a homoaromatic or heteroaromatic ring system; A is a single bond or an unsubstituted or substituted divalent C.sub.1-30 bridging group; Y is O or S; and Z is Cl, Br, I, N.sub.3, N-succinimidyloxy, imidazolyl, 1-benzotriazolyloxy, OAr where Ar is an electron-deficient activating aryl group, or OC(O)R where R is --A--Q--N.dbd.C.dbd.Y or C.sub.4-20 tertiary-alkyl. A method for activating an amine function towards reaction with a second amine involves reacting the amine with the foregoing linker. The resultant isocyanate or isothiocyanate derivative can then be reacted with a second amine to form a urea or thiourea conjugate.The linker is useful for producing conjugates of ligands with amine-containing polymers and/or proteins, especially for forming antibody conjugates with chelators, drugs, enzymes, detectable labels and the like.

Abstract: A process for the electrodeposition of a nickel chromium alloy on a catho substrate comprises:contacting the substrate with an aqueous electrolyte containing: about 50-125 g/l of CrCl.sub.3.6H.sub.2 O; about 10-125 g/l of NiCl.sub.2.6H.sub.2 O; about 10-115 g/l of formic acid; about 25-50 g/l of boric acid; and about 50-100 g/l of sodium citrate dihydrate;adjusting the pH of the bath to about 1-5 and the temperature to about 20.degree.-60.degree. C.; andpassing a sufficient current through the solution and to the substrate to effect deposition thereon of a nickel-chromium alloy.